QUESTIONSOcular Diseases & Drug Discovery (Ocular2009)
Venue: Philadelphia
Location: Philadelphia, Pennsylvania, United States
| Event Date/Time: Apr 20, 2009 | End Date/Time: Apr 21, 2009 |
| Registration Date: Apr 21, 2009 | |
| Early Registration Date: Mar 20, 2009 |
Report as SpamDescription
Due to the unmet needs of ocular disease drug therapies and the growing population of aging individuals, GTCbio is proud to announce its inaugural Ocular Diseases & Drug Discovery conference, taking place on April 20-21, 2009 in Philadelphia, PA.
In 2005, the National Eye Institute (NEI) estimated that the annual cost of vision impairment and eye disease to the United States was $68 billion. Not only are eye diseases costly to the US, they also impact the quality of life of over 34 million people, causing lost productivity, reduced independence, diminished quality of life, increased depression and accelerated mortality. By 2020, this number is expected to grow to over 50 million.
Several companies have taken the initiative in developing ocular disease therapies, including companies such as Pfizer, EyeGate, pSivida, Merck, Regeneron, Genzyme, Novartis, Ophthotech, Macusight, Neurotech, GlaxoSmithKline and many more. To help promote the discovery and developments of ocular disease, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research & drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the Ocular Diseases & Drug Discovery conference.
The conference features the following sessions:
Session I: Aged Macular Degeneration
Session II: Retinal Diseases
Session III: Other Ocular Diseases
Session IV: Recent Drug Developments & Mechanisms in Ocular Diseases
Session V: Future of Ocular Diseases Therapeutics
Session VI: Novel Drug Delivery Methods
In 2005, the National Eye Institute (NEI) estimated that the annual cost of vision impairment and eye disease to the United States was $68 billion. Not only are eye diseases costly to the US, they also impact the quality of life of over 34 million people, causing lost productivity, reduced independence, diminished quality of life, increased depression and accelerated mortality. By 2020, this number is expected to grow to over 50 million.
Several companies have taken the initiative in developing ocular disease therapies, including companies such as Pfizer, EyeGate, pSivida, Merck, Regeneron, Genzyme, Novartis, Ophthotech, Macusight, Neurotech, GlaxoSmithKline and many more. To help promote the discovery and developments of ocular disease, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research & drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the Ocular Diseases & Drug Discovery conference.
The conference features the following sessions:
Session I: Aged Macular Degeneration
Session II: Retinal Diseases
Session III: Other Ocular Diseases
Session IV: Recent Drug Developments & Mechanisms in Ocular Diseases
Session V: Future of Ocular Diseases Therapeutics
Session VI: Novel Drug Delivery Methods
